LBPO.IM01 · 免疫学 · Late-Breaking

巨噬细胞-树突状细胞-T细胞四联体协调抗肿瘤免疫和对检查点阻断的反应

Macrophage-dendritic cell-T-cell tetrads orchestrate antitumor immunity and response to checkpoint blockade

海报缩略图:巨噬细胞-树突状细胞-T细胞四联体协调抗肿瘤免疫和对检查点阻断的反应
编号 LB086 展板 12 时间 4/19 02:00–05:00 区域 Section 54 主讲 Mehdi Chaib, PhD
分会场 Late-Breaking Research: Immunology 1
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Mehdi Chaib, Muhammad Aminu, Shelley Herbrich, Mahshid Arabi, Yue Xuan, Akshay Basi, Anna Casasent, Marc Macaluso, Kenneth Hu, Matthew Gubin, Xi Chen, James Mancuso, Sreyashi Basu, Sonali Jindal, Jared Burks, Stephanie Watowich, Jia Wu, James Allison, Padmanee Sharma

UT MD Anderson Cancer Center, Houston, TX

摘要 Abstract

中文摘要
免疫检查点抑制剂(ICI)仅在一部分实体瘤患者中引发持久反应,这凸显了明确支配有效抗肿瘤免疫的细胞结构的必要性。在此,我们鉴定了一个空间组织的多细胞免疫单元,由巨噬细胞、cDC1、CD4⁺ T细胞和CD8⁺ T细胞组成,它在响应抗CTLA-4或双重检查点阻断时出现。我们将这些结构称为"四联体"。通过在小鼠和人类肿瘤中使用多重成像和空间转录组学,我们展示四联体在免疫致敏早期组装、依赖于ICOS-ICOSL通路,并富集ICOS⁺ Th1样CD4⁺ T细胞和ICOSL高表达cDC1。四联体内的CD8⁺ T细胞表现出活化的、非终末分化状态,而四联体相关的巨噬细胞则显示出一种干扰素-γ反应性程序,维持CD8⁺ T细胞功能并防止其功能障碍。在功能上,ICOSL⁺ cDC1是体内肿瘤根除所必需的。在接受新辅助双重检查点阻断治疗的膀胱癌患者中,四联体(而非三联体或二联体)的形成与临床反应相关。这些发现将四联体确立为协调抗肿瘤免疫和对ICI反应性的基本细胞单元。
查看英文原文 English abstract
Immune checkpoint inhibitors (ICIs) elicit durable responses in only a subset of patients with solid tumors, underscoring the need to define the cellular architectures that govern effective antitumor immunity. Here we identify a spatially organized multicellular immune unit comprising macrophages, cDC1s, CD4⁺ T-cells, and CD8⁺ T-cells that emerges in response to anti-CTLA-4 or dual checkpoint blockade. We term these structures tetrads . Using multiplexed imaging and spatial transcriptomics in mouse and human tumors, we show that tetrads assemble early during immune priming, depend on the ICOS-ICOSL pathway, and are enriched for ICOS⁺ Th1-like CD4⁺ T cells and ICOSL high cDC1s. CD8⁺ T-cells within tetrads exhibit an activated, non-terminally differentiated state, while tetrad-associated macrophages display an interferon-gamma-responsive program that sustains CD8⁺ T-cell function and prevents dysfunction. Functionally, ICOSL⁺ cDC1s are required for tumor eradication in vivo . In patients with bladder cancer treated with neoadjuvant dual checkpoint blockade, tetrad, but not triad or dyad formation correlates with clinical response. These findings establish tetrads as a fundamental cellular unit coordinating antitumor immunity and responsiveness to ICIs.
利益披露 Disclosure
M. Chaib, None.. M. Aminu, None.. S. Herbrich, None.. M. Arabi, None.. Y. Xuan, None.. A. Basi, None.. A. Casasent, None.. M. Macaluso, None.. K. Hu, None.. M. Gubin, None.. X. Chen, None.. J. Mancuso, None.. S. Basu, None.. S. Jindal, None.. J. Burks, None.. S. Watowich, None.. J. Wu, None.. J. Allison, None.. P. Sharma, None.

← 返回 AACR 2026 检索